Breast Cancer

Ibrance approved for the treatment of HR+, HER2- advanced or metastatic breast cancer.

Antibody-drug conjugates and immunotherapy harness immune system to target breast cancer tumors.

Investigators seek to stop women's cancers before it starts to form.

Emend found to provide a greater delay in nausea and vomiting from cancer treatment than other medicines.

Emend found to provide a greater delay in nausea and vomiting from cancer treatment than other medicines.

Early detection is key in reducing the risk of heart failure in patients with cancer.

New research may transform oncology drug development.

Researchers warn political interference may discourage shared decision-making in breast cancer treatment.

Researchers examine use of docetaxel in patients with castration-resistant metastatic prostate cancer following androgen-deprivation therapy.

Researchers examine use of docetaxel in patients with castration-resistant metastatic prostate cancer following androgen-deprivation therapy.

Researchers examine how genetic changes in breast cancer cells interfere with pathways critical to disease growth and survival.

Research examines long non-coding RNAs as biomarkers and therapeutic targets.

Discovery can help predict progression to metastatic cancer.

Out-of-pocket costs to remain a significant hurdle for patients even after closing of coverage gap.

Measured and unmeasured costs can have a significant impact on outcomes for patients with cancer.

A new study conducted by researchers at Kaiser Permanente has found that a considerable number of working-age adults who survive cancer and its toxic treatments, end up with substantial medical debts or declare bankruptcy.

Treatment shows the potential to turn metastatic breast tumors into low-grade tumors.

Study finds adoption of Medicaid expansion could reduce disparities in breast cancer screening.

Palbociclib has been found effective inhibiting the mobilization of enzymes that contribute to the rapid division of tumor cells.

Research may lead to new treatment approach for cancer.

Revenue not expected to maintain pace of current immunology treatments.

Severity and type of symptoms varies among cancer patients in different age groups.

Out-of-pocket costs to remain a significant hurdle for patients even after closing of coverage gap.

Vistogard treats patients who develop life-threatening toxicities within days of receiving cancer drugs.

Chemosensitivity, treatment variations, and socioeconomic factors may be a significant factor.